Glycot Therapeutics LLC

Ellicott City, MD

UEI
Q9DESREWJJ39
CAGE
7FQT6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
4991 Wild Olive Court, Ellicott City, MD 21042, USA
Website
glycot.com
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation R44GM153003 National Institute of General Medical Sciences (NIH) $4,230,480
Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific… R43GM146537 National Institute of General Medical Sciences (NIH) $642,478
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins R44GM134816 National Institute of General Medical Sciences (NIH) $2,202,266
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins R43GM134816 National Institute of General Medical Sciences (NIH) $300,000
Chemoenzymatic synthesis of stable isotope-labeled glycopeptides as internal standards for glycosylation quantitation R43GM128547 National Institute of General Medical Sciences (NIH) $292,823

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Glycoscientific, L.L.C. UEI EUVNNWGFCA87 Athens, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Z Biotech, LLC UEI KTUKAUTZVRJ3 Aurora, CO 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Natglycan LLC UEI NMMMHXNPL8U5 Tucker, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Lectenz Bio, Inc. UEI JTGCK219C6F4 Athens, GA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
IHP Therapeutics Inc. UEI MASZJLS7DHK3 San Carlos, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Glycot Therapeutics LLC is a for-profit limited liability company that specializes in developing innovative chemoenzymatic platforms for glycoengineering therapeutic proteins, particularly antibodies. Registered with the federal government since 2015, the company focuses on creating streamlined, efficient methods for site-specific glycan remodeling and antibody conjugation. Glycot's proprietary technologies aim to improve the efficacy and stability of antibody-based therapeutics, with applications ranging from cancer treatment to targeted protein degradation.

Through multiple federal grant awards from the National Institute of General Medical Sciences (NIGMS), Glycot Therapeutics has been advancing its glycoengineering platforms. The company's projects have included scaling up the synthesis of disaccharide substrates, demonstrating compatibility with engineered human IgG, developing simplified fusion enzyme constructs, and optimizing processes for synthesizing glycan-specific antibody-drug conjugates (ADCs). Glycot's work has focused on overcoming limitations in existing antibody conjugation methods, offering more precise control over drug-to-antibody ratios and improved pharmacokinetics. The company aims to provide both convenient kits for academic researchers and comprehensive services for industrial partners to develop and evaluate antibody conjugate candidates. Glycot's grant-funded research has encompassed the development of immobilized enzymes, scalable glycan production methods, and the creation of streamlined chemoenzymatic systems for glycan remodeling of antibodies and other glycoproteins.

Quick answers

Is Glycot Therapeutics LLC registered in SAM.gov?

Yes. Glycot Therapeutics LLC's SAM.gov registration is active through April 4, 2027.

What is Glycot Therapeutics LLC's most recent federal award?

Glycot Therapeutics LLC's most recent federal grant award is Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation (R44GM153003), from National Institute of General Medical Sciences (NIH), on March 1, 2024.

On GovTribe

See Glycot Therapeutics LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login